Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174603 · ClinicalTrials.gov registry record · Phase 3
Treatment of Depression With Quetiapine
A Phase 3 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00174603 is a Phase 3 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT00174603, a Phase 3 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the mood stabilizing and antipsychotic properties of quetiapine in the treatment of depression by comparing subjects who were randomly assigned to either quetiapine monotherapy, quetiapine and citalopram; or haloperidol and citalopram. We hypothesize that quetiapine monotherapy would have similar effects to the combination of a first generation antipsychotic plus an antidepressant for the treatment of a major depressive episode with psychosis.
Interventions
- DRUG quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174603
The ClinicalTrials.gov registry entry for NCT00174603 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which quetiapine is the first listed.
NCT00174603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174603 about?
NCT00174603 is a clinical study titled "Treatment of Depression With Quetiapine". The purpose of this study is to examine the mood stabilizing and antipsychotic properties of quetiapine in the treatment of depression by comparing subjects who were randomly assigned to either quetiapine monotherapy, quetiapine and citalopram; or haloperidol and citalopram. We hypothesize that quet...
What is the current status of trial NCT00174603?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2005-08. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00174603?
The interventions under investigation include: quetiapine (DRUG).
Who is sponsoring clinical trial NCT00174603?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.